½ÃÀ庸°í¼­
»óǰÄÚµå
1446784

Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå : Á¦Ç° À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«) - ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)

Therapeutic Apheresis Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 178 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Persistence Market Research´Â À̹ø¿¡ ¼¼°èÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀåÀÇ »ó¼¼ ºÐ¼®À» ¹ßÇ¥Çϰí, ÁÖ¿ä ½ÃÀå ¿ªÇÐ, ¼ºÀå ÃËÁø¿äÀΡ¤°úÁ¦, ½Å±Ô µ¿ÇâÀÇ Á¾ÇÕÀû °³¿ä¸¦ Á¦°øÇß½À´Ï´Ù. Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀåÀÇ ±¸Á¶¿¡ °üÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí, 2023-2030³â ½ÃÀåÀÇ ¼ºÀå ±Ëµµ¸¦ ¿¹ÃøÇÏ´Â µ¶Á¡ µ¥ÀÌÅÍ¿Í Åë°è¸¦ Á¦½ÃÇϰí ÀÖ½À´Ï´Ù.

Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀåÀº ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR) 7.2%·Î ¼ºÀåÇϸç, 2023³â 28¾ï ´Þ·¯¿¡¼­ 2030³â¸»¿¡´Â 46¾ï ´Þ·¯·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

  • Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå ±Ô¸ð(2023 E) : ¹Ì±¹ : 28¾ï ´Þ·¯
  • ¿¹Ãø ½ÃÀå ±Ô¸ð(2030 F) : 46¾ï ´Þ·¯
  • ¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2023-2030³â) : 7.2%
  • °ú°Å ½ÃÀå ¼ºÀå·ü(2018-2022³â CAGR) : 6.8%

Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå - ¸®Æ÷Æ® ¹üÀ§ :

Ä¡·áÀû ¾ÆÆä·¹½Ã½º(Ç÷ÀåÁ¦°Å¼úÀ̶ó°íµµ ÇÔ)´Â ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº Áõ»óÀ» Ä¡·áÇϱâ À§ÇØ Æ¯Á¤ Ç÷¾× ¼ººÐÀ» ÃßÃâ, ºÐ¸®, ȯ¿øÇÏ´Â ÀÇ·á ½Ã¼úÀÔ´Ï´Ù. ½Å°æ°è ¹× Ç÷¾×ÇÐ ÁúȯÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ °Ç°­ ¹®Á¦¸¦ °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ ¹× Ç÷¾×ÁúȯÀÇ À¯º´·ü Áõ°¡, ±â¼ú ¹ßÀü, ÀÇ·á Àü¹®°¡µéÀÇ ÀÎ½Ä Áõ°¡ µîÀÌ ¼¼°è ½ÃÀå È®´ë ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Ä¡·áÀû ¾ÆÆç·¹½Ã½º Ä¡·áÁ¦·Î Ä¡·áÇÒ ¼ö ÀÖ´Â Áúȯ¿¡ Ãë¾àÇÑ Àα¸ÀÇ °í·ÉÈ­µµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸ ¹× ±â¼ú ºÐ¾ßÀÇ Çù·ÂÀû ³ë·ÂÀº Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀåÀÇ Áö¼ÓÀûÀÎ È®ÀåÀ» º¸ÀåÇϸç Áøº¸¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ÃËÁø¿äÀÎ:

¸· ºÐ¸® ¹× ÀÚµ¿È­ Àåºñ¿Í °°Àº Ä¡·áÀû ¾ÆÆä·¹½Ã½º ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ±â¼ú Çõ½ÅÀº Á¤È®¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Ç÷¾× ¼ººÐÀÇ ÃßÃâÀ» °³¼±ÇÏ°í ºÎÀÛ¿ëÀ» ÁÙÀ̸ç ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÚµ¿È­ ½Ã½ºÅÛÀº ÀϰüµÈ ÃßÃâÀ» º¸ÀåÇϰí ÅëÇÕ ¼ÒÇÁÆ®¿þ¾î´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç °áÁ¤À» À§ÇÑ ½Ç½Ã°£ Çǵå¹éÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ÅëÇÕÀº ½Å°æ Áúȯ ¹× ÀÚ°¡ ¸é¿ª Áúȯ°ú °°ÀÌ È¿À²ÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â ÁúȯÀÇ ¹üÀ§¸¦ ³ÐÈú ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

Ä¡·áÀû ¾ÆÆä·¹½Ã½º °ü·Ã Áß¿äÇÑ ¹ßÀü°ú ÀåÁ¡¿¡µµ ºÒ±¸Çϰí, ¾÷°è´Â ÀçÁ¤Àû Á¦¾àÀ̶ó´Â Å« Àå¾Ö¹°¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ³ôÀº Ãʱ⠼³Á¤ ºñ¿ë, Áö¼ÓÀûÀÎ À¯Áöº¸¼ö ºñ¿ë, Àü¹® ÀηÂÀÇ Çʿ伺 µîÀº ÀÇ·á ±â°ü°ú ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô »ó´çÇÑ ÀçÁ¤Àû ºÎ´ãÀ» ¾È°ÜÁÖ°í ÀÖ½À´Ï´Ù. ÷´Ü ħ¼ú Àåºñ¸¦ ±¸ÀÔÇÏ°í ¾ö°ÝÇÑ ¾ÈÀü ÇÁ·ÎÅäÄÝÀ» ±¸ÇöÇÏ´Â µ¥ ÇÊ¿äÇÑ ¸·´ëÇÑ ÅõÀÚ·Î ÀÎÇØ ¼Ò±Ô¸ð ÀÇ·á ±â°üÀÌ Ä§¼ú Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ ħ¼ú Ä¡·á¸¦ ÅëÇÕÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

±ÔÁ¦ À庮°ú Ç¥ÁØÈ­ÀÇ º¹À⼺À¸·Î ÀÎÇØ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. Àϰü¼º ¾ø´Â ±ÔÁ¦ Áöħ°ú ´Ù¾çÇÑ ±â¼úµéÀÌ ¾ÆÆç·¹½Ã½º ½Ã¼úÀÇ Ã¤ÅÃÀ» ¹æÇØÇϰí, Ç¥ÁØÈ­µÈ º£½ºÆ® ÇÁ·¢Æ¼½ºÀÇ È®¸³À» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Çõ½ÅÀûÀÎ ¾ÆÆç·¹½Ã½º ±â¼úÀÇ ½ÂÀΰú ½ÃÇàÀº ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ Ã¶ÀúÇÑ °ËÁõÀ» °ÅÃÄ¾ß ÇÕ´Ï´Ù.

½ÃÀå ±âȸ :

Ä¡·áÀû ¾ÆÆä·¹½Ã½ºÀÇ È®´ë´Â Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ Àû¿ë È®´ë°¡ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¤È®¼º°ú ¼±ÅüºÀ» °®Ãá ¾ÆÆç·¹½Ã½º ½Ã¼úÀº Èñ±Í À¯Àü Áúȯ ¹× ƯÁ¤ ¾ÏÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áúȯ¿¡ ´ëÇÑ ¸ÂÃãÇü Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. Ä¡·áÀû ¾ÆÆç·¹½Ã½º´Â À¯ÀüÇÐÀÚ, ¾ÆÆç·¹½Ã½º Àü¹®°¡ ¹× ±âŸ ÀÇ·á ºÐ¾ß °£ÀÇ Çù¾÷À» ÃËÁøÇÏ¿© ¸ÂÃãÇü ÀǷḦ À§ÇÑ À¯¸ÁÇÑ ¹æ¹ýÀÔ´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • Ä¡·áÀû ¾ÆÆä·¹½Ã½º ¼ö¿ä¸¦ ÁÖµµÇÏ´Â »ê¾÷º° ¼ö¿ä´Â?
  • ±â¼úÀÇ ¹ßÀüÀÌ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå °æÀï ±¸µµ¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?
  • ¼¼°è Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀåÀ» ¼±µµÇÏ´Â ¾÷ü´Â?
  • ¼¼°è Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀåÀÇ »õ·Î¿î Æ®·»µå¿Í Àü¸ÁÀº?

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

  • ½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ÁÖ¿ä µ¿Çâ
  • ½Ã¼ú À¯Çü ¼ö¸íÁֱ⠺м®
  • Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå : ¹ë·ùüÀÎ
    • ¿øÀç·á °ø±Þ¾÷ü ¸®½ºÆ®
    • Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÆÇ¸Å ´ë¸®Á¡ ¸®½ºÆ®
    • ¿ëµµ ¸®½ºÆ®
    • ¼öÀͼº ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÁöÁ¤ÇÐÀû ±äÀå : ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ
  • °Å½Ã°æÁ¦Àû ¿äÀÎ
    • ¼¼°èÀÇ ºÎ¹®º° Àü¸Á
    • ¼¼°èÀÇ GDP ¼ºÀå·ü Àü¸Á
    • ¼¼°èÀÇ ¸ð½ÃÀå °³¿ä
  • ¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
  • ±ÔÁ¦¿Í Å×Å©³î·¯Áö »óȲ

Á¦3Àå ¼¼°èÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : °ú°Å(2018-2022³â)¿Í ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
    • ½ÃÀå ¼ö·®(À¯´Ö) ¿¹Ãø
    • ½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü
    • Àý´ëÀû ±Ý¾× ±âȸ
  • ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø
    • °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, 2013-2016³â
    • ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, 2018-2026³â
  • ¼¼°èÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : ½Ã¼úÀÇ À¯Çü
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • 2018-2022³âÀÇ ½Ã¼ú À¯Çüº° °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ¾ç(´ÜÀ§)ÀÇ ºÐ¼®
    • ÇöÀç ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ½Ã¼ú À¯Çüº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
      • Ä¡·á¿ë Ç÷À屳ȯ(TPE)
      • ÀûÇ÷±¸ ±³È¯(RBCX)
      • ¼¼Æ÷ °í°¥
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ½Ã¼ú À¯Çü
  • ¼¼°èÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : Å×Å©³î·¯Áö
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • 2018-2022³âÀÇ Å×Å©³î·¯Áöº° °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯) ¹× ¼ö·®(´ÜÀ§) ºÐ¼®
    • ÇöÀç ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ±â¼úº° ¼ö·®(´ÜÀ§) ¿¹Ãø, 2023-2030³â
      • ¿ø½ÉºÐ¸®
      • ¸·¿©°ú
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Å×Å©³î·¯Áö
  • ¼¼°èÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : ¿ëµµ
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
    • ÇöÀç ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ¿¹Ãø, 2023-2030³â
      • Ç÷¾×ÇÐ
      • ½Å°æ ³»°ú
      • ½ÅÀåÇÐ
      • ·ù¸¶Æ¼½º°ú
      • Á¾¾çÇÐ
      • ±âŸ
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ¿ëµµ
  • ¼¼°èÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚ
    • ¼­·Ð/ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ÃÖÁ¾»ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
    • ÇöÀç ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ÃÖÁ¾»ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ¿¹Ãø, 2023-2030³â
      • º´¿ø
      • Ç÷¾×ÀºÇà
      • Àü¹® Ŭ¸®´Ð
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚ

Á¦4Àå ¼¼°èÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : Áö¿ª

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • Áö¿ªº° °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯) ¹× ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
  • ÇöÀç ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í Áö¿ªº° ¼ö·®(´ÜÀ§) ¿¹Ãø, 2023-2030³â
    • ºÏ¹Ì
    • À¯·´
    • µ¿¾Æ½Ã¾Æ
    • ³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ª

Á¦5Àå ºÏ¹ÌÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : °ú°Å(2018-2022³â)¿Í ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
    • ±¹°¡º°
      • ¹Ì±¹
      • ij³ª´Ù
    • ½Ã¼ú À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦6Àå À¯·´ÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : °ú°Å(2018-2022³â)¿Í ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
    • ±¹°¡º°
      • µ¶ÀÏ
      • ÇÁ¶û½º
      • ¿µ±¹
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ·¯½Ã¾Æ
      • ÅÍŰ
      • ±âŸ À¯·´
    • ½Ã¼ú À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦7Àå µ¿¾Æ½Ã¾ÆÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : °ú°Å(2018-2022³â)¿Í ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
    • ±¹°¡º°
      • Áß±¹
      • ÀϺ»
      • Çѱ¹
    • ½Ã¼ú À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°

Á¦8Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : °ú°Å(2018-2022³â)¿Í ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
    • ±¹°¡º°
      • Àεµ
      • µ¿³²¾Æ½Ã¾Æ
      • ´ºÁú·£µå
      • ±âŸ ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
    • ½Ã¼ú À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦9Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : °ú°Å(2018-2022³â)¿Í ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
    • ±¹°¡º°
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
    • ½Ã¼ú À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ä¡·áÀû ¾ÆÆä·¹½Ã½º ½ÃÀå Àü¸Á : °ú°Å(2018-2022³â)¿Í ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð(¸¸ ´Þ·¯)¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®, 2018-2022³â
    • ±¹°¡º°
      • GCC
      • ÀÌÁýÆ®
      • ³²¾ÆÇÁ¸®Ä«
      • ºÏ¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½Ã¼ú À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â
  • ½ÃÀå ±¸Á¶
    • ½ÃÀ庰 °æÀï °­µµ ¸ÅÇÎ
    • °æÀï ´ë½Ãº¸µå
    • º¸ÀÌ´Â ½Ã¼ú À¯Çü ¿ë·®
  • ±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
    • Asahi Kasei Medical Co.
    • Haemonetics Corporation
    • Miltenyi Biotec
    • Cerus Corporation
    • Terumo BCT Inc.
    • Fresenius Kabi USA
    • Terumo Bct
    • B. Braun Melsungen AG
    • Nikkiso Co. Ltd.
    • Medica SpA
    • Baxter Healthcare Corporation
    • Kawasumi Laboratories Inc.
    • Therakos Incorporation

Á¦12Àå ºÎ·Ï

  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ °¡Á¤
  • µÎÀÚ¾î¿Í ¾à¾î
KSA 24.04.04

Persistence Market Research has recently published an in-depth analysis of the global Therapeutic Apheresis Market, offering a comprehensive overview of key market dynamics, growth drivers, challenges, and emerging trends. This report provides valuable insights into the structure of the Therapeutic Apheresis Market, presenting exclusive data and statistics that forecast the market's growth trajectory from 2023 to 2030.

The therapeutic apheresis market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.2%, leading to a rise from US$2.8 billion in 2023 to US$4.6 billion by the conclusion of 2030.

Key Insights:

  • Therapeutic Apheresis Market Size (2023E): US$2.8 Bn
  • Projected Market Value (2030F): US$4.6 Bn
  • Global Market Growth Rate (CAGR 2023 to 2030): 7.2%
  • Historical Market Growth Rate (CAGR 2018 to 2022): 6.8%

Therapeutic Apheresis Market- Report Scope:

Therapeutic apheresis, also known as plasmapheresis, is a medical procedure extracting, separating, and returning specific blood components to treat conditions like autoimmune diseases. It plays a crucial role in managing various health issues, including neurological and hematologic conditions. Factors driving the global market expansion include the increasing incidence of autoimmune and hematologic disorders, technological advancements, and growing awareness among healthcare professionals. The aging population, susceptible to conditions treatable with therapeutic apheresis, also contributes to market growth. Collaborative efforts in research and technology further fuel advancements, ensuring the continued expansion of the therapeutic apheresis market.

Market Growth Drivers:

Continuous technological innovations in therapeutic apheresis, such as membrane-based separation and automated devices, enhance precision and safety. These advancements improve blood component extraction, reduce adverse events, and increase patient comfort. Automated systems ensure consistent extraction, and integrated software provides real-time feedback for informed decision-making. This integration of technology broadens the scope of efficiently managed ailments, including neurological and autoimmune disorders.Top of Form

Market Restraints:

Despite the significant advancements and benefits associated with therapeutic apheresis, the industry faces a significant obstacle in the form of financial constraints. High initial setup costs, ongoing maintenance expenses, and the need for specialized personnel impose a considerable financial burden on healthcare institutions and providers. The substantial investment required for acquiring advanced apheresis equipment and enforcing stringent safety protocols often hinders smaller healthcare facilities from incorporating therapeutic apheresis into their treatment protocols.

Regulatory hurdles and standardization complexities hinder the therapeutic apheresis market's growth. Inconsistent regulatory guidelines and diverse technologies impede the adoption of apheresis procedures and hinder the establishment of standardized best practices. Additionally, the approval and implementation of innovative apheresis technologies require thorough scrutiny to ensure safety and efficacy.

Market Opportunities:

The expansion of therapeutic apheresis is driven by its increasing application in precision medicine. With its precision and selectivity, apheresis procedures offer tailored treatments for various diseases, including uncommon genetic disorders and specific cancers. Therapeutic apheresis holds promise for personalized healthcare, fostering collaboration among geneticists, apheresis specialists, and other healthcare fields.

Key Questions Answered in the Report:

  • What are the key factors driving the growth of the therapeutic apheresis market?
  • Which industry verticals are driving the demand for therapeutic apheresis?
  • How are technological advancements reshaping the competitive landscape of the therapeutic apheresis market?
  • Who are the leading players in the global therapeutic apheresis market?
  • What are the emerging trends and future prospects in the global therapeutic apheresis market?

Competitive Intelligence and Business Strategy:

Key players in the global therapeutic apheresis market, including Fresenius, Haemonetics, Terumo BCT, and Asahi Kasei, prioritize innovation and product enhancement. They invest in research and development to introduce advanced technologies, solidifying their leadership. Strategic collaborations with healthcare organizations and research institutions contribute to market growth, providing insights into emerging trends. To expand market share, these companies target regions with high healthcare demand, forming alliances, establishing distribution networks, and adapting marketing strategies to regional regulations.

Key Companies Profiled:

  • Asahi Kasei Medical Co.
  • Haemonetics Corporation
  • Miltenyi Biotec
  • Cerus Corporation
  • Terumo BCT Inc.
  • Fresenius Kabi USA
  • Terumo BCT
  • B. Braun Melsungen AG
  • Nikkiso Co. Ltd.
  • Medica S.p.A.
  • Baxter Healthcare Corporation
  • Kawasumi Laboratories Inc.
  • Therakos Incorporation

Therapeutic Apheresis Market Segmentation:

By Procedure Type:

  • Therapeutic Plasma Exchange (TPE)
  • Red Blood Cell Exchange (RBCX)
  • Cellular Depletions

By Technology:

  • Centrifugation
  • Membrane filtration

By Application:

  • Hematology
  • Neurology
  • Nephrology
  • Rheumatology
  • Oncology
  • Others

By End User:

  • Hospitals
  • Blood banks
  • Specialty clinics

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Therapeutic Apheresis Market Snapshot, 2023 and 2030
  • 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Procedure Types Lifecycle Analysis
  • 2.4. Therapeutic Apheresis Market: Value Chain
    • 2.4.1. List of Raw Material Supplier
    • 2.4.2. List of Manufacturers
    • 2.4.3. List of Distributors
    • 2.4.4. List of Applications
    • 2.4.5. Profitability Analysis
  • 2.5. Porter Five Force's Analysis
  • 2.6. Geopolitical Tensions: Market Impact
  • 2.7. Macro-Economic Factors
    • 2.7.1. Global Sectorial Outlook
    • 2.7.2. Global GDP Growth Outlook
    • 2.7.3. Global Parent Market Overview
  • 2.8. Forecast Factors - Relevance and Impact
  • 2.9. Regulatory and Technology Landscape

3. Global Therapeutic Apheresis Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 3.1. Key Highlights
    • 3.1.1. Market Volume (Units) Projections
    • 3.1.2. Market Size and Y-o-Y Growth
    • 3.1.3. Absolute $ Opportunity
  • 3.2. Market Size (US$ Mn) Analysis and Forecast
    • 3.2.1. Historical Market Size Analysis, 2013-2016
    • 3.2.2. Current Market Size Forecast, 2018-2026
  • 3.3. Global Therapeutic Apheresis Market Outlook: Procedure Types
    • 3.3.1. Introduction / Key Findings
    • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Procedure Types, 2018 - 2022
    • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Procedure Types, 2023 - 2030
      • 3.3.3.1. Therapeutic Plasma Exchange (TPE)
      • 3.3.3.2. Red Blood Cell Exchange (RBCX)
      • 3.3.3.3. Cellular Depletions
  • 3.4. Market Attractiveness Analysis: Procedure Types
  • 3.5. Global Therapeutic Apheresis Market Outlook: Technology
    • 3.5.1. Introduction / Key Findings
    • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Technology, 2018 - 2022
    • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
      • 3.5.3.1. Centrifugation
      • 3.5.3.2. Membrane filtration
  • 3.6. Market Attractiveness Analysis: Technology
  • 3.7. Global Therapeutic Apheresis Market Outlook: Application
    • 3.7.1. Introduction / Key Findings
    • 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Application, 2018 - 2022
    • 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
      • 3.7.3.1. Hematology
      • 3.7.3.2. Neurology
      • 3.7.3.3. Nephrology
      • 3.7.3.4. Rheumatology
      • 3.7.3.5. Oncology
      • 3.7.3.6. Others
  • 3.8. Market Attractiveness Analysis: Application
  • 3.9. Global Therapeutic Apheresis Market Outlook: End User
    • 3.9.1. Introduction / Key Findings
    • 3.9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By End User, 2018 - 2022
    • 3.9.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
      • 3.9.3.1. Hospitals
      • 3.9.3.2. Blood banks
      • 3.9.3.3. Specialty clinics
  • 3.10. Market Attractiveness Analysis: End User

4. Global Therapeutic Apheresis Market Outlook: Region

  • 4.1. Key Highlights
  • 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
  • 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. East Asia
    • 4.3.4. South Asia and Oceania
    • 4.3.5. Latin America
    • 4.3.6. Middle East & Africa (MEA)
  • 4.4. Market Attractiveness Analysis: Region

5. North America Therapeutic Apheresis Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 5.1. Key Highlights
  • 5.2. Pricing Analysis
  • 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 5.3.1. By Country
    • 5.3.2. By Procedure Types
    • 5.3.3. By Technology
    • 5.3.4. By Application
    • 5.3.5. By End User
  • 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 5.4.1. U.S.
    • 5.4.2. Canada
  • 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Procedure Types, 2023 - 2030
    • 5.5.1. Therapeutic Plasma Exchange (TPE)
    • 5.5.2. Red Blood Cell Exchange (RBCX)
    • 5.5.3. Cellular Depletions
  • 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 5.6.1. Centrifugation
    • 5.6.2. Membrane filtration
  • 5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 5.7.1. Hematology
    • 5.7.2. Neurology
    • 5.7.3. Nephrology
    • 5.7.4. Rheumatology
    • 5.7.5. Oncology
    • 5.7.6. Others
  • 5.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 5.8.1. Hospitals
    • 5.8.2. Blood banks
    • 5.8.3. Specialty clinics
  • 5.9. Market Attractiveness Analysis

6. Europe Therapeutic Apheresis Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 6.3.1. By Country
    • 6.3.2. By Procedure Types
    • 6.3.3. By Technology
    • 6.3.4. By Application
    • 6.3.5. By End User
  • 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 6.4.1. Germany
    • 6.4.2. France
    • 6.4.3. U.K.
    • 6.4.4. Italy
    • 6.4.5. Spain
    • 6.4.6. Russia
    • 6.4.7. Turkiye
    • 6.4.8. Rest of Europe
  • 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Procedure Types, 2023 - 2030
    • 6.5.1. Therapeutic Plasma Exchange (TPE)
    • 6.5.2. Red Blood Cell Exchange (RBCX)
    • 6.5.3. Cellular Depletions
  • 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 6.6.1. Centrifugation
    • 6.6.2. Membrane filtration
  • 6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 6.7.1. Hematology
    • 6.7.2. Neurology
    • 6.7.3. Nephrology
    • 6.7.4. Rheumatology
    • 6.7.5. Oncology
    • 6.7.6. Others
  • 6.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 6.8.1. Hospitals
    • 6.8.2. Blood banks
    • 6.8.3. Specialty clinics
  • 6.9. Market Attractiveness Analysis

7. East Asia Therapeutic Apheresis Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 7.3.1. By Country
    • 7.3.2. By Procedure Types
    • 7.3.3. By Technology
    • 7.3.4. By Application
    • 7.3.5. By End User
  • 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. South Korea
  • 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Procedure Types, 2023 - 2030
    • 7.5.1. Therapeutic Plasma Exchange (TPE)
    • 7.5.2. Red Blood Cell Exchange (RBCX)
    • 7.5.3. Cellular Depletions
  • 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 7.6.1. Centrifugation
    • 7.6.2. Membrane filtration
  • 7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 7.7.1. Hematology
    • 7.7.2. Neurology
    • 7.7.3. Nephrology
    • 7.7.4. Rheumatology
    • 7.7.5. Oncology
    • 7.7.6. Others
  • 7.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 7.8.1. Hospitals
    • 7.8.2. Blood banks
    • 7.8.3. Specialty clinics
  • 7.9. Market Attractiveness Analysis

8. South Asia & Oceania Therapeutic Apheresis Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 8.3.1. By Country
    • 8.3.2. By Procedure Types
    • 8.3.3. By Technology
    • 8.3.4. By Application
    • 8.3.5. By End User
  • 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 8.4.1. India
    • 8.4.2. Southeast Asia
    • 8.4.3. ANZ
    • 8.4.4. Rest of South Asia & Oceania
  • 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Procedure Types, 2023 - 2030
    • 8.5.1. Therapeutic Plasma Exchange (TPE)
    • 8.5.2. Red Blood Cell Exchange (RBCX)
    • 8.5.3. Cellular Depletions
  • 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 8.6.1. Centrifugation
    • 8.6.2. Membrane filtration
  • 8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 8.7.1. Hematology
    • 8.7.2. Neurology
    • 8.7.3. Nephrology
    • 8.7.4. Rheumatology
    • 8.7.5. Oncology
    • 8.7.6. Others
  • 8.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 8.8.1. Hospitals
    • 8.8.2. Blood banks
    • 8.8.3. Specialty clinics
  • 8.9. Market Attractiveness Analysis

9. Latin America Therapeutic Apheresis Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 9.3.1. By Country
    • 9.3.2. By Procedure Types
    • 9.3.3. By Technology
    • 9.3.4. By Application
    • 9.3.5. By End User
  • 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America
  • 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Procedure Types, 2023 - 2030
    • 9.5.1. Therapeutic Plasma Exchange (TPE)
    • 9.5.2. Red Blood Cell Exchange (RBCX)
    • 9.5.3. Cellular Depletions
  • 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 9.6.1. Centrifugation
    • 9.6.2. Membrane filtration
  • 9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 9.7.1. Hematology
    • 9.7.2. Neurology
    • 9.7.3. Nephrology
    • 9.7.4. Rheumatology
    • 9.7.5. Oncology
    • 9.7.6. Others
  • 9.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 9.8.1. Hospitals
    • 9.8.2. Blood banks
    • 9.8.3. Specialty clinics
  • 9.9. Market Attractiveness Analysis

10. Middle East & Africa Therapeutic Apheresis Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 10.3.1. By Country
    • 10.3.2. By Procedure Types
    • 10.3.3. By Technology
    • 10.3.4. By Application
    • 10.3.5. By End User
  • 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 10.4.1. GCC
    • 10.4.2. Egypt
    • 10.4.3. South Africa
    • 10.4.4. Northern Africa
    • 10.4.5. Rest of Middle East & Africa
  • 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Procedure Types, 2023 - 2030
    • 10.5.1. Therapeutic Plasma Exchange (TPE)
    • 10.5.2. Red Blood Cell Exchange (RBCX)
    • 10.5.3. Cellular Depletions
  • 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 10.6.1. Centrifugation
    • 10.6.2. Membrane filtration
  • 10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 10.7.1. Hematology
    • 10.7.2. Neurology
    • 10.7.3. Nephrology
    • 10.7.4. Rheumatology
    • 10.7.5. Oncology
    • 10.7.6. Others
  • 10.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 10.8.1. Hospitals
    • 10.8.2. Blood banks
    • 10.8.3. Specialty clinics
  • 10.9. Market Attractiveness Analysis

11. Competition Landscape

  • 11.1. Market Share Analysis, 2022
  • 11.2. Market Structure
    • 11.2.1. Competition Intensity Mapping By Market
    • 11.2.2. Competition Dashboard
    • 11.2.3. Apparent Procedure Types Capacity
  • 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 11.3.1. Asahi Kasei Medical Co.
      • 11.3.1.1. Overview
      • 11.3.1.2. Segments and Procedure Types
      • 11.3.1.3. Key Financials
      • 11.3.1.4. Market Developments
      • 11.3.1.5. Market Strategy
    • 11.3.2. Haemonetics Corporation
      • 11.3.2.1. Overview
      • 11.3.2.2. Segments and Procedure Types
      • 11.3.2.3. Key Financials
      • 11.3.2.4. Market Developments
      • 11.3.2.5. Market Strategy
    • 11.3.3. Miltenyi Biotec
      • 11.3.3.1. Overview
      • 11.3.3.2. Segments and Procedure Types
      • 11.3.3.3. Key Financials
      • 11.3.3.4. Market Developments
      • 11.3.3.5. Market Strategy
    • 11.3.4. Cerus Corporation
      • 11.3.4.1. Overview
      • 11.3.4.2. Segments and Procedure Types
      • 11.3.4.3. Key Financials
      • 11.3.4.4. Market Developments
      • 11.3.4.5. Market Strategy
    • 11.3.5. Terumo BCT Inc.
      • 11.3.5.1. Overview
      • 11.3.5.2. Segments and Procedure Types
      • 11.3.5.3. Key Financials
      • 11.3.5.4. Market Developments
      • 11.3.5.5. Market Strategy
    • 11.3.6. Fresenius Kabi USA
      • 11.3.6.1. Overview
      • 11.3.6.2. Segments and Procedure Types
      • 11.3.6.3. Key Financials
      • 11.3.6.4. Market Developments
      • 11.3.6.5. Market Strategy
    • 11.3.7. Terumo Bct
      • 11.3.7.1. Overview
      • 11.3.7.2. Segments and Procedure Types
      • 11.3.7.3. Key Financials
      • 11.3.7.4. Market Developments
      • 11.3.7.5. Market Strategy
    • 11.3.8. B. Braun Melsungen AG
      • 11.3.8.1. Overview
      • 11.3.8.2. Segments and Procedure Types
      • 11.3.8.3. Key Financials
      • 11.3.8.4. Market Developments
      • 11.3.8.5. Market Strategy
    • 11.3.9. Nikkiso Co. Ltd.
      • 11.3.9.1. Overview
      • 11.3.9.2. Segments and Procedure Types
      • 11.3.9.3. Key Financials
      • 11.3.9.4. Market Developments
      • 11.3.9.5. Market Strategy
    • 11.3.10. Medica S.p.A.
      • 11.3.10.1. Overview
      • 11.3.10.2. Segments and Procedure Types
      • 11.3.10.3. Key Financials
      • 11.3.10.4. Market Developments
      • 11.3.10.5. Market Strategy
    • 11.3.11. Baxter Healthcare Corporation
      • 11.3.11.1. Overview
      • 11.3.11.2. Segments and Procedure Types
      • 11.3.11.3. Key Financials
      • 11.3.11.4. Market Developments
      • 11.3.11.5. Market Strategy
    • 11.3.12. Kawasumi Laboratories Inc.
      • 11.3.12.1. Overview
      • 11.3.12.2. Segments and Procedure Types
      • 11.3.12.3. Key Financials
      • 11.3.12.4. Market Developments
      • 11.3.12.5. Market Strategy
    • 11.3.13. Therakos Incorporation
      • 11.3.13.1. Overview
      • 11.3.13.2. Segments and Procedure Types
      • 11.3.13.3. Key Financials
      • 11.3.13.4. Market Developments
      • 11.3.13.5. Market Strategy

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Research Assumptions
  • 12.3. Acronyms and Abbreviations
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦